Joseph J. Galligan - 30 Sep 2022 Form 4 Insider Report for BioCorRx Inc. (BICX)

Role: Director, 10%+ Owner
Signature: /s/ Joseph J. Galligan
Issuer symbol: BICX
Transactions as of: 30 Sep 2022
Net transactions value: +$299,768
Form type: 4
Filing time: 06 Jul 2023, 08:27:57 UTC
Previous filing: 08 Jul 2022
Next filing: 03 Oct 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BICX	Common Stock, par value $0.001	Award	$0	+2,450	+6.4%	$0.000000	40,931	30 Sep 2022	Direct	F1
transaction	BICX	Common Stock, par value $0.001	Award	$0	+5,319	+13%	$0.000000	46,250	30 Dec 2022	Direct	F2
transaction	BICX	Common Stock, par value $0.001	Purchase	$299,768	+171,296	+370%	$1.75	217,546	29 Mar 2023	By Trust	F3
transaction	BICX	Common Stock, par value $0.001	Award	$0	+2,824	+1.3%	$0.000000	220,370	31 Mar 2023	Direct	F4
transaction	BICX	Common Stock, par value $0.001	Award	$0	+2,891	+1.3%	$0.000000	223,261	30 Jun 2023	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.04.
F2	These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.94.
F3	These shares were issued to The J and R Galligan Revocable Trust, managed by Mr. Joseph M. Galligan (the "Galligan Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Galligan Trust dated March 29 2023, and paid for on March 30, 2023. The Reporting Person may be deemed to have investment power over the Galligan Trust.
F4	These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.77.
F5	These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.73.